Katherine E. Kollef; Richard M. Reichley, RPh; Scott T. Micek, PharmD; and Marin H. Kollef, MD, FCCP
|
|
- Samuel Jeffry Poole
- 6 years ago
- Views:
Transcription
1 CHEST Original Research The Modified Score Outperforms Curb65 Pneumonia Severity Score as a Predictor of 30-Day Mortality in Patients With Methicillin- Resistant Staphylococcus aureus Pneumonia* Katherine E. Kollef; Richard M. Reichley, RPh; Scott T. Micek, PharmD; and Marin H. Kollef, MD, FCCP PNEUMONIA Objective: To compare the predictive accuracy for 30-day mortality of the CURB65 score adopted by the British Thoracic Society and the simpler CRB65 score to APACHE (acute physiology and chronic health evaluation) II in patients with methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Design: A retrospective, single-center, observational cohort study. Setting: Barnes-Jewish Hospital, a 1,200-bed urban teaching hospital. Patients: Adult patients requiring hospitalization identified to have MRSA pneumonia. Interventions: Retrospective data collection from automated hospital, microbiology, and pharmacy databases. Measurements and main results: Two hundred eighteen patients with MRSA pneumonia were identified over a 3-year period. Forty-four patients (20.2%) died during hospitalization. All three prediction rules had high negative predictive values but relatively low positive predictive values at most cut-off points examined. had the greatest area under the receiver operating characteristic curve (0.805; 95% confidence interval [CI], to 0.866) compared to CURB65 (0.634; 95% CI, to 0.727) and CRB65 (0.643; 95% CI, to 0.739) [p < 0.05 for both comparisons]. Similar results were obtained when the subgroups of community-acquired MRSA pneumonia and health-care associated MRSA pneumonia were examined separately. Conclusions: outperformed CURB65 and CRB65 for initial prognostic assessment in MRSA pneumonia. (CHEST 2008; 133: ) Key words: ; CRB65; CURB65; methicillin-resistant Staphylococcus aureus; pneumonia Abbreviations: APACHE acute physiology and chronic health evaluation; BJC Barnes-Jewish-Christian; CAP community-acquired pneumonia; CI confidence interval; Fio 2 fraction of inspired oxygen; MRSA methicillinresistant Staphylococcus aureus; ROC receiver operating characteristic Pneumonia due to methicillin-resistant Staphylococcus aureus (MRSA) is becoming increasingly more common both in the health-care setting and in the community. 1 4 Hospital mortality associated with MRSA pneumonia has been reported to be between 20% and 40%. 1,5 9 Most patients with MRSA pneumonia will require hospitalization, frequently being admitted to the ICU settings and often requiring ventilatory support. 10 Given the increasing prevalence and importance of MRSA pneumonia, clinical trials are likely to be planned examining new treatment modalities, the changing epidemiology of For editorial comment see page 336 MRSA pneumonia, and prevention strategies. To date, a validated prediction tool for clinical outcomes in patients with MRSA pneumonia has not been identified. Several international organizations have developed guidelines or scoring systems in an attempt to stratify CHEST / 133 / 2/ FEBRUARY,
2 patients with community-acquired pneumonia (CAP) according to risk severity Unfortunately, the use of similar methods for patients with health-care associated pneumonia, including MRSA pneumonia, have not been developed. Given the increasing prevalence of MRSA pneumonia and the future need for new clinical research, we designed a study with two main goals. Our first goal was to compare the accuracy of three prediction rules (modified APACHE [acute physiology and chronic health evaluation] II, CURB65, CRB65) to predict 30-day mortality in patients with MRSA pneumonia. Our second goal was to compare these prediction tools in patients admitted to the hospital with the community-acquired MRSA pneumonia phenotype and those acquiring healthcare associated MRSA pneumonia. Study Location and Patients Materials and Methods This study was conducted at a university-affiliated, urban teaching hospital: Barnes-Jewish Hospital (1,200 beds). During a 3-year period (January 2003 to June 2005), all hospitalized patients with MRSA pneumonia, microbiologically confirmed by BAL cultures, and treated with either vancomycin or linezolid monotherapy were eligible for this investigation. Patients with polymicrobial infection demonstrated by BAL cultures, requiring other antimicrobial treatment, and those treated with either vancomycin or linezolid for 72 h were excluded from evaluation. This study was approved by the Washington University School of Medicine Human Studies Committee, and informed consent was waived. Study Design and Data Collection A retrospective cohort study design was employed with the main outcome measure being 30-day mortality. A computerized list of patients with MRSA pneumonia was generated by the Medical Informatics Department through retrospective query of the Microbiology Laboratory database at Barnes-Jewish Hospital (performed by R.M.R.), which allowed identification of potential study patients. Patients could not be entered into the study more than once. At Barnes-Jewish Hospital, patients with MRSA pneumonia can be treated with vancomycin (15 mg/kg body weight IV q12h) or linezolid (600 mg IV q12h). Patients treated *From the Division of Pulmonary and Critical Care Medicine (Dr. Kollef and Ms. Kollef), Washington University School of Medicine; Center for Quality and Effectiveness (Mr. Reichley), BJC Healthcare; and Department of Pharmacy Practice (Dr. Micek), St. Louis College of Pharmacy, St. Louis, MO. The authors have no conflicts of interest to report regarding this article. Manuscript received July 25, 2007; revision accepted September 24, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: Marin H. Kollef, MD, FCCP, Campus Box 8052, Washington University School of Medicine, 660 South Euclid Ave, St. Louis, MO 63110; mkollef@im.wustl.edu DOI: /chest with vancomycin can have their dosing and interval of dosing adjusted based on their underlying renal function. Definitions and Outcome Scoring Systems All definitions were selected prospectively as part of the original study design. scores were calculated based on clinical data available on the day the BAL was performed confirming the diagnosis of MRSA pneumonia. 19 A modified score was employed in that assessment of the Glasgow coma score was not included. The CURB65 and CRB65 scores were calculated based on the criteria specified in the original articles. 16,17 The confusion variable employed in this study was not the same as in the original definition of CURB65. The definition of confusion for CURB 65 was an Abbreviated Mental Test Score 8 or new disorientation to person, place, or time. 16 We assessed confusion only as a report of new disorientation to person, place, or time as documented in the medical records. The, CURB65, and CRB65 scores were computed by one investigator (K.E.K.) to avoid interobserver variability. Thirty-day mortality was assessed from the time when the diagnostic BAL for MRSA pneumonia was performed. For patients discharged prior to the 30-day cutoff for mortality evaluation, a computerized medical records search was undertaken to determine if hospital readmission and death had occurred. All 11 hospitals in the Barnes-Jewish-Christian (BJC) Healthcare system have a common computerized medical records system allowing tracking of patients at all system hospitals. A clinical diagnosis of MRSA pneumonia was based on criteria modified from those established by the American College of Chest Physicians. 20 These criteria require the occurrence of new and persistent radiographic infiltrates in conjunction with two of the following: fever, leukocytosis, and purulent tracheal aspirate or sputum. In addition to the clinical criteria for MRSA pneumonia, BAL cultures with appropriate quantitative thresholds were obtained bronchoscopically to support the diagnosis of MRSA pneumonia. Quantitative thresholds of 10 4 cfu/ml for MRSA were considered positive for the diagnosis of MRSA pneumonia. The community-acquired phenotype of MRSA was defined as isolates resistant to methicillin but sensitive to three or more of the following antibiotics: gentamicin, ciprofloxacin, trimethopim-sulfamethoxazole, and clindamycin. For purposes of this study health-care associated MRSA pneumonia included all patients hospitalized for 2 days prior to obtaining a positive BAL culture result, and patients with a first positive BAL culture result within 2 days of hospital admission whose isolates did not meet the criteria for the community-acquired phenotype of MRSA and who possessed any of the following: admission from another health-care facility including nursing homes, use of long-term hemodialysis, immunosuppression, and prior hospitalization within 30 days. 21 Microbiological Data The microbiology laboratory performed antimicrobial susceptibility of clinical isolates by the Kirby-Bauer disk diffusion method according to guidelines and break points established by the Clinical Laboratory and Standards Institute, using 150-mm round plates of Mueller-Hinton agar (BBL; Becton-Dickinson; Cockeysville, MD). A technologist experienced in reading zones of inhibition with a ruler against a black background measured the zone diameters manually. Statistical Analysis All comparisons were unpaired and all tests of significance were two-tailed. Continuous variables were compared using the 364 Original Research
3 Table 1 Definition of Performance Characteristics* Performance Characteristics Definition Equation Sensitivity (how good is the test at identifying patients who will die?) Specificity (how good is the test at identifying patients who will not die?) Positive predictive value (in the event of a positive test result, the probability that the patient will die) Negative predictive value (in the event of a negative test result, the probability that the patient will not die) ROC True-positive results (ie, tested positive and died); all deaths True-negative results (ie, tested negative and lived); all alive True-positive results; all positives True-negatives results; all negatives A curve created by mapping sensitivity against 1 specificity. The AUC is a marker of performance with higher values indicating better diagnostic ability. An AUC 1 indicates perfect performance, whereas an AUC 0.5 indicates that there is a 50:50 chance that the test correctly identifies those who die *Sensitivity and specificity are useful when considering the performance of a test at the population level. In contrast, positive predictive value and negative predictive value are better when considering the performance of a test at the patient level (ie, in the event of a positive test result, what is the probability that the patient will or will not die?). AUC area under the curve. Student t test for normally distributed variables and the Mann- Whitney U test for nonnormally distributed variables. The 2 or Fisher exact test was used to compare categorical variables. The primary data analysis compared 30-day nonsurvivors with survivors. We performed multiple logistic-regression analysis using statistical software (SPSS, version 11.0 for Windows; SPSS; Chicago, IL). Multivariate analysis was performed using models that were judged a priori to be clinically sound. 22 This was prospectively determined to be necessary to avoid producing spuriously significant results with multiple comparisons. All potential risk factors significant at the 0.15 level in univariate analyses were entered into the model. Sensitivity, specificity, positive predictive value, negative predictive value, and the areas under the receiver operating characteristic (ROC) curves for predicting 30-day mortality in each prediction rule were compared using the definitions shown in Table 1. ROC curves were generated for the population as a whole and then for the patients with the community-acquired phenotype of MRSA and those with health-care associated MRSA pneumonia, respectively. For all analyses, a two-tailed p value 0.05 was considered statistically significant. Results Patient Characteristics A total of 218 patients with microbiologically confirmed MRSA pneumonia were evaluated at Barnes-Jewish Hospital during the study period. Mean age of the population was years ( SD) [range, 19 to 92 years]; there were 141 male (64.7%) and 77 female (35.3%) patients. Patient characteristics and outcomes are provided in Table 2. Mean score was (range, 3 to 37). Mean CURB65 and CRB65 scores were (range, 0 to 5) and (range, 0 to 4), respectively. Among the 178 patients treated with vancomycin and having trough levels measured, mean trough value for vancomycin collected after the third dose was g/ml. Thirty-Day Mortality Forty-four patients (20.2%) died within 30 days of the development of MRSA pneumonia. Two hundred five patients (94.0%) required ICUs admission, and 167 patients (76.6%) received tracheal intubation and mechanical ventilation. Nonsurvivors were Table 2 Baseline Patient Characteristics and Outcomes* Variables 30-Day Survivors (n 174) 30-Day Nonsurvivors (n 44) p Value Age, yr Gender Male 114 (65.5) 27 (61.4) 0.61 Female 60 (34.5) 17 (38.6) Race Caucasian 122 (70.1) 35 (79.5) 0.21 African American 52 (29.9) 9 (20.5) Pao 2 /Fio Comorbidities COPD 58 (33.3) 17 (38.6) 0.51 Coronary artery disease 29 (16.7) 14 (31.8) 0.02 Underlying malignancy 38 (21.8) 10 (22.7) 0.90 Diabetes 43 (24.7) 11 (25.0) 0.97 End-stage renal disease 4 (2.3) 6 (13.6) 0.01 Immunosuppression 27 (15.5) 3 (6.8) 0.22 Processes of care Antibiotic with 12 h 129 (74.1) 33 (75.0) 0.91 Antibiotic within 24 h 144 (82.8) 38 (86.4) 0.57 Mechanical ventilation 124 (71.3) 43 (97.7) 0.01 Vasopressors 17 (9.8) 17 (38.6) 0.01 Antibiotic Vancomycin 157 (90.2) 40 (90.9) 0.99 Linezolid 17 (9.8) 4 (9.1) MRSA phenotype Community acquired 33 (19.0) 8 (18.8) 0.91 Health-care associated 141 (81.0) 36 (81.2) *Data are presented as mean SD or No. (%). CHEST / 133 / 2/ FEBRUARY,
4 Table 3 Sensitivity, Specificity, and Positive and Negative Predictive Values of 30-Day Mortality of the Different Prediction Rules* Cut-off Points Mortality Sensitivity Specificity Positive Predictive Value Negative Predictive Value CURB /13 (0.0) n/a 1 18/108 (16.7) /78 (21.8) /15 (33.3) /3 (100) /1 (100) CRB /118 (13.6) n/a 1 18/80 (22.5) /16 (37.5) /3 (100) /1 (100) /4 (0.0) n/a /13 (0.0) /61 (1.6) /50 (12.0) /45 (37.8) /31 (45.2) /14 (42.9) *Data are presented as No. total (%). n/a not applicable. Cut-off points accepted as threshold to define a low-risk group according to original study design. 16,17 statistically more likely to require mechanical ventilation compared to survivors (Table 2). Prediction of 30-Day Mortality Patients dying within 30 days of onset of MRSA pneumonia had statistically greater scores ( vs ; p 0.01), CURB65 scores ( vs ; p 0.01), and CRB65 scores ( vs ; p 0.01) compared to patients surviving 30 days. Table 3 shows the sensitivity, specificity, and positive and negative predictive values for 30-day mortality at different cut-off points for each scoring system. had higher sensitivities than CURB65 and CRB65 at all risk levels. All three prediction rules had high negative predictive values but relatively low positive predictive values at most of the cut-off points examined. ROC curves for 30-day mortality for each prediction scoring method are shown in Figure 1. The area under the ROC curve for was statistically greater than the areas under the ROC curves for CURB65 and CRB65: (95% confidence interval [CI], to 0.866) vs (95% CI, to 0.727) and (95% CI, to 0.739), respectively (p 0.05 for both comparisons). Similar results were obtained when the ROC curves were compared for the patients with the communityacquired phenotype (n 41) of MRSA and the health-care associated phenotype (n 177) [Fig 2, 3]. Of note, the area under the ROC curve for was greatest for the communityacquired phenotype compared to the overall population and the health-care associated phenotype. Two separate logistic regression analyses were performed due to concern over colinearity between CRB65 and. Logistic regression analysis identified increasing scores, increasing CRB65, decreasing Pao 2 /fraction of inspired oxygen (Fio 2 ), and vasopressor use as independent predic- Sensitivity 1 - Specificity Source of the Curve Reference Line CUR65 CURB65 Figure 1. ROC curve for each prognostic tool (n 218). The area under the ROC curves are as follows:, (95% CI, to 0.866); CURB65, (95% CI, to 0.727); CRB65, (95% CI, to 0.739). 366 Original Research
5 Table 4 Multivariate Analysis of Independent Risk Factors for 30-Day Mortality* Variables Adjusted Odds Ratio 95% CI p Value Sensitivity tors of 30-day mortality in the two models (Table 4). CRB65 provided a model that held a better fit to the data compared to CURB65 based on the Hosmer- Lemeshow goodness-of-fit statistic. Discussion We showed that the modified score outperformed the CURB65 and CRB65 pneumonia severity scores as a predictor of 30-day mortality in patients with MRSA pneumonia. Analysis of the ROC curves demonstrated that the modified score was statistically superior to both CURB65 and CRB65 as a predictor of 30-day mortality. This was true for patients with the community-acquired phenotype of Sensitivity 1 - Specificity 1 - Specificity Source of the Curve Reference Line CUR65 CURB65 Figure 3. ROC curve for each prognostic tool for patients with the community-acquired phenotype of MRSA (n 41). The area under the ROC curves are as follows:, (95% CI, to 0.994); CURB65, (95% CI, to 0.951); and CRB65, (95% CI, 01 to 0.949). Source of the Curve Reference Line CUR65 CURB65 Figure 2. ROC curve for each prognostic tool for patients with health-care associated MRSA pneumonia (n 177). The area under the ROC curves are as follows:, (95% CI, to 0.855); CURB65, (95% CI, 00 to 0.708); and CRB65, (95% CI, to 0.727). Model 1 score (1-point increments) Pao 2 /Fio (1-point decrements) Model 2 CRB (1-point increments) Pao 2 /Fio (1-point decrements) Vasopressor use *Because of colinearity between variables included in and CRB65, two separate models are displayed, with only one of these two variables entered into each model, respectively. Other covariates not presented in the table had a p value 0.05 including age, presence of coronary artery disease, end-stage renal disease, and mechanical ventilation. The Hosmer-Lemeshow goodness-of-fit findings for each model are p 0.23 and p 0.94, respectively. MRSA pneumonia as well as those with health-care associated MRSA pneumonia. However, in our multivariate models both and CRB65 were independent predictors of 30-day mortality. The odds of death by day 30 was greater for CRB65, which, in large part, was related to the smaller number of discriminating units in CRB65 compared to APACHE II. Nevertheless, the ROC curves suggest that for individual patient predictions, is more accurate than CRB65. CURB65 and CRB65 have been validated as tools to predict mortality and the need for ICU admission in patients with CAP. 16,17 These scoring systems are easy to employ, and the CRB65 requires only data immediately available at the time of clinical evaluation. More recent studies have further demonstrated the utility of CURB65 and CRB65 as outcome predictors in CAP. Man et al 23 found that CURB65 and CRB65 were accurate predictors of 30-day mortality among patients in Hong Kong with CAP. Similarly, Barlow et al 24 found that CURB65 outperformed generic sepsis scores as a predictor of mortality. Both of these studies had ROC curve areas in the range of 0.69 to 0.78, which were higher than the values observed in our study. The main differences are that these previous evaluations of CURB65 and CRB65 involved patients with CAP with a variety of infectious pathogens. Our study differed by involving only hospitalized patients with either community-acquired or health-care associated MRSA pneumonia. Other investigators have attempted to identify predictors of mortality in patients with nosocomial pneumonia. Combes et al 25 identified the Sepsis- CHEST / 133 / 2/ FEBRUARY,
6 Related Organ Failure Assessment as a predictor of 28-day mortality when measured on day 1, day 3, and day 8 following onset of ventilator-associated pneumonia. Similar studies focusing on MRSA pneumonia are not available. Rello et al 26 evaluated a cohort of patients with MRSA pneumonia optimally treated with glycopeptide antibiotics. They found that bacteremia and the absence of vancomycin administration by a continuous infusion were associated with intensive care mortality. They did not identify severity of illness using as a predictor of mortality in their study. Their study cohort differed from ours in being smaller, from four different hospitals, and selected to be included in a study of glycopeptide optimization. Kollef et al 21 evaluated 4,543 patients with CAP, hospital-acquired pneumonia, ventilator-associated pneumonia, and health-care associated pneumonia. MRSA was the most common single pathogen identified in patients with health-care associated pneumonia and the second most common pathogen in hospitalassociated pneumonia. Although a severity-of illness score was not evaluated in that study, independent predictors of hospital mortality included those variables that make up the score (age, coma, ph value, creatinine value, WBC count, temperature, and respiratory rate). Several important limitations of this investigation should be noted. First, we employed the CURB65 scoring system that has previously only been validated in CAP while not examining other pneumonia prediction tools including the Pneumonia Severity Index. This may be an important reason why the CURB65 did not perform as well in patients with MRSA pneumonia. We also performed this study at a single center, limiting the application of these results to other hospitals. More studies are warranted to determine the optimal prediction tool for patients with nosocomial pneumonia including MRSA. We limited our analysis to patients with microbiologically confirmed MRSA pneumonia. Therefore, we do not know the comparative accuracy of these prediction scores in patients with clinically diagnosed MRSA pneumonia. Moreover, the study results may be confounded due to the retrospective nature of this analysis. Another important limitation is that we only tracked patients within one hospital system. It is possible that we may have missed patient deaths occurring after hospital discharge but within 30 days in individuals not readmitted to a BJC Healthcare hospital. Finally, we used a modified calculation, relied on medical chart review to assess confusion for the CURB65 and CRB65 measurements, and limited the mortality assessment to 30 days, which may all limit the overall applicability of these data to other populations. In summary, we found that a modified APACHE II score outperformed CURB65 and CRB65 in predicting 30-day mortality in MRSA pneumonia. Future studies are needed to corroborate these results and to develop better prediction tools for patients with nosocomial pneumonia. References 1 Naimi TS, LeDell KH, Como-Sabetti K, et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003; 290: Hageman JC, Uyeki TM, Francis JS, et al. Severe communityacquired pneumonia due to Staphylococcus aureus, influenza season. Emerg Infect Dis 2006; 12: Pujol M, Corbella X, Pena C, et al. Clinical and epidemiological findings in mechanically-ventilated patients with methicillin-resistant Staphylococcus aureus pneumonia. Eur J Clin Microbiol Infect Dis 1998; 17: Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive communityacquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128: Rello J, Torres A, Ricart M, et al. Ventilator-associated pneumonia by Staphylococcus aureus: comparison of methicillin-resistant and methicillin-sensitive episodes. Am J Respir Crit Care Med 1994; 150: Gonzalez C, Rubio M, Romero-Vivas J, et al. Bacteremic pneumonia due to Staphylococcus aureus: a comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 1999; 29: Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002; 359: Wunderink RG, Rello J, Cammarata SK, et al. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: Jeffres MN, Isakow W, Doherty JA, et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: American Thoracic Society (ATS), Infectious Diseases Society of America (IDSA). Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: British Thoracic Society Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56:IV1 IV64 12 Mandell LA, Marrie TJ, Grossman RF, et al. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society; the Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31: Bartlett JG, Dowell SF, Mandell LA, et al. Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America. Clin Infect Dis 2000; 31: Niederman MS, Mandell LA, Anzueto A, et al. American Thoracic Society guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: Original Research
7 15 Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: Neill AM, Martin IR, Weir R, et al. Community acquired pneumonia: aetiology and usefulness of severity criteria on admission. Thorax 1996; 51: Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44:S27 S72 19 Knaus WA, Draper EA, Wagner DP, et al. : a severity of disease classification system. Crit Care Med 1985; 13: Pingleton SK, Fagon JY, Leeper KV Jr. Patient selection for clinical investigation of ventilator-associated pneumonia: criteria for evaluating diagnostic techniques. Chest 1992; 102: 553s 556s 21 Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of healthcare-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: Concato JA, Feinstein F, Holford TR. The risk of determining risk with multivariate models. Ann Intern Med 1993; 118: Man SY, Lee N, Ip M, et al. Prospective comparison of three predictive rules for assessing severity of communityacquired pneumonia in Hong Kong. Thorax 2007; 62: Barlow G, Nathwani D, Davey P. The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia. Thorax 2007; 62: Combes A, Luyt CE, Fagon JY, et al. Early predictors for infection recurrence and death in patients with ventilatorassociated pneumonia. Crit Care Med 2007; 35: Rello J, Sole-Violan J, Sa-Borges M, et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005; 33: CHEST / 133 / 2/ FEBRUARY,
MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES
MDR AGENTS: RISK FACTORS AND THERAPEUTIC STRATEGIES 1 Marin H. Kollef, MD Professor of Medicine Virginia E. and Sam J. Golman Chair in Respiratory Intensive Care Medicine Washington University School of
More informationThorax Online First, published on May 20, 2008 as /thx
Thorax Online First, published on May 20, 2008 as 10.1136/thx.2008.095562 Systolic Blood Pressure is Superior to Other Haemodynamic Predictors of Outcome in Community Acquired Pneumonia James D Chalmers
More informationRepeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia
ORIGINAL ARTICLE Repeated Pneumonia Severity Index Measurement After Admission Increases its Predictive Value for Mortality in Severe Community-acquired Pneumonia Chiung-Zuei Chen, 1 Po-Sheng Fan, 2 Chien-Chung
More informationClinical Therapeutics/Volume 29, Number 6, 2007
Clinical Therapeutics/Volume 29, Number 6, 2007 A Retrospective Analysis of Possible Renal Toxicity Associated with Vancomycin in Patients with Health Care Associated Methicillin-Resistant Staphylococcus
More informationPneumonia Severity Scores:
Pneumonia Severity Scores: Are they Accurate Predictors of Mortality? JILL McEWEN, MD FRCPC Clinical Professor Department of Emergency Medicine University of British Columbia Vancouver, BC Canada President,
More informationCare Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline DRAFT for review cycle 08/02/17 CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: All MHS employed providers within Primary Care, Urgent Care, and In-Hospital Care. The secondary audience
More informationCARE OF THE ADULT PNEUMONIA PATIENT
Care Guideline CARE OF THE ADULT PNEUMONIA PATIENT Target Audience: The target audience for this Care Guideline is all MultiCare providers and staff, including those associated with our clinically integrated
More informationDelayed Administration of Antibiotics and Atypical Presentation in Community-Acquired Pneumonia*
CHEST Delayed Administration of Antibiotics and Atypical Presentation in Community-Acquired Pneumonia* Grant W. Waterer, MD, FCCP; Lori A. Kessler, PharmD; and Richard G. Wunderink, MD, FCCP Original Research
More informationCommunity-Acquired Pneumonia OBSOLETE 2
Community-Acquired Pneumonia OBSOLETE 2 Clinical practice guidelines serve as an educational reference, and do not supersede the clinical judgment of the treating physician with respect to appropriate
More informationA Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU*
CHEST Original Research A Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU* Marcos I. Restrepo, MD, MSc, FCCP; Eric M. Mortensen, MD, MSc; Jose A. Velez, MD;
More informationKey words: community acquired; epidemiology; health care; mechanical ventilation; mortality; nosocomial; outcomes; pneumonia; resource use
Epidemiology and Outcomes of Health-care Associated Pneumonia* Results From a Large US Database of Culture-Positive Pneumonia Marin H. Kollef, MD, FCCP; Andrew Shorr, MD, MPH, FCCP; Ying P. Tabak, PhD;
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationClinical characteristics of health care-associated pneumonia in a Korean teaching hospital
Respiratory Medicine (2010) 104, 1729e1735 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Clinical characteristics of health care-associated pneumonia in a Korean teaching
More informationK L Buising, K A Thursky, J F Black, L MacGregor, A C Street, M P Kennedy, G V Brown...
419 RESPIRATORY INFECTION A prospective comparison of severity scores for identifying patients with severe community acquired pneumonia: reconsidering what is meant by severe pneumonia K L Buising, K A
More informationMaking the Right Call With. Pneumonia. Community-acquired pneumonia (CAP) is a. Community-Acquired. What exactly is CAP?
Making the Right Call With Community-Acquired Pneumonia In this article: By Thomas J. Marrie, MD The case of Allyson Allyson, 32, presented to the emergency department with a 48-hour history of anorexia,
More informationI n the assessment and management of community acquired
377 RESPIRATORY INFECTION Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study W S Lim, M M van der Eerden, R Laing, W G Boersma,
More informationPredictors of Outcomes of Community Acquired Pneumonia in Egyptian Older Adults
Original Contribution/Clinical Investigation Predictors of Outcomes of Community Acquired Pneumonia in Egyptian Older Adults Hossameldin M. M. Abdelrahman Amal E. E. Elawam Ain Shams University, Faculty
More informationS evere community acquired pneumonia (CAP) is an
421 RESPIRATORY INFECTION Validation of predictive rules and indices of severity for community acquired pneumonia S Ewig, A de Roux, T Bauer, E García, J Mensa, M Niederman, A Torres... See end of article
More informationS evere community acquired pneumonia (CAP) is an
421 RESPIRATORY INFECTION Validation of predictive rules and indices of severity for community acquired pneumonia S Ewig, A de Roux, T Bauer, E García, J Mensa, M Niederman, A Torres... See end of article
More informationPolmoniti: Steroidi sì, no, quando. Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma
Polmoniti: Steroidi sì, no, quando Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma Number of patients Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive
More informationThe Burden of Viruses in Pneumonia Associated With Acute Respiratory Failure An Underappreciated Issue
[ Original Research ] The Burden of Viruses in Pneumonia Associated With Acute Respiratory Failure An Underappreciated Issue Andrew F. Shorr, MD, MPH; Kristen Fisher, MD; Scott T. Micek, PharmD; and Marin
More informationYun-Xia Chen 1, Jun-Yu Wang 1 and Shu-Bin Guo 1,2*
Chen et al. Critical Care (2016) 20:167 DOI 10.1186/s13054-016-1351-0 RESEARCH Use of CRB-65 and quick Sepsis-related Organ Failure Assessment to predict site of care and mortality in pneumonia patients
More informationClinical Guidelines for Use of Antibiotics. VANCOMYCIN (Adult)
VANCOMYCIN (Adult) Please always prescribe VANCOMYCIN in the Variable Dose Antibiotic section of the EPMA SUPPLEMENTARY drug chart (and add a placeholder on the electronic drug chart). 1 Background Vancomycin
More informationThe clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii
Journal of Infection (2011) 63, 351e361 The clinical implication and prognostic predictors of Tigecycline treatment for pneumonia involving multidrug-resistant Acinetobacter baumannii R 陳南丞 VS 余文良醫師 本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時,
More informationTo develop guidelines for the use of appropriate antibiotics for adult patients with CAP and guidance on IV to PO conversion.
Page 1 of 5 TITLE: COMMUNITY-ACQUIRED PNEUMONIA (CAP) EMPIRIC MANAGEMENT OF ADULT PATIENTS AND IV TO PO CONVERSION GUIDELINES: These guidelines serve to aid clinicians in the diagnostic work-up, assessment
More informationORIGINAL ARTICLE DOI: (e) ISSN Online: (p) ISSN Print: Anand Kumar Singh 1, Poonam Verma 2. Sciences, Dehradun
ORIGINAL ARTICLE CLINICAL ASSESSMENT OF NEPHROTOXICITY ASSOCIATED WITH VANCOMYCIN TROUGH CONCENTRATIONS DURING TREATMENT OF DEEP-SEATED INFECTIONS: A RETROSPECTIVE ANALYSIS Anand Kumar Singh 1, Poonam
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationCHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement
CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement Evidence-Based Assessment of Diagnostic Tests for Ventilator- Associated Pneumonia* Executive Summary Ronald F. Grossman, MD, FCCP; and Alan Fein, MD,
More informationDiagnosis of Ventilator- Associated Pneumonia: Where are we now?
Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Gary French Guy s & St. Thomas Hospital & King s College, London BSAC Guideline 2008 Masterton R, Galloway A, French G, Street M, Armstrong
More informationKAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA
KAISER PERMANENTE OHIO COMMUNITY ACQUIRED PNEUMONIA Methodology: Expert opinion Issue Date: 8-97 Champion: Pulmonary Medicine Most Recent Update: 6-08, 7-10, 7-12 Key Stakeholders: Pulmonary Medicine,
More informationAn evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia
ORIGINAL ARTICLE EPIDEMIOLOGY An evaluation of clinical stability criteria to predict hospital course in community-acquired pneumonia A. R. Akram 1, J. D. Chalmers 1, J. K. Taylor 2, J. Rutherford 2, A.
More informationAbstract. Introduction
ORIGINAL ARTICLE INFECTIOUS DISEASES Accuracy of American Thoracic Society/Infectious Diseases Society of America criteria in predicting infection or colonization with multidrug-resistant bacteria at intensive-care
More informationClinical Features And Correlates Of Bacteremia Among Urban Minority New Yorkers Hospitalized With Community Acquired Pneumonia
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 7 Number 2 Clinical Features And Correlates Of Bacteremia Among Urban Minority New Yorkers Hospitalized With Community Acquired Pneumonia B Kanna,
More informationC ommunity-acquired pneumonia (CAP) is an important
253 PNEUMONIA The CURB65 pneumonia severity score outperforms generic sepsis and early warning scores in predicting mortality in community-acquired pneumonia Gavin Barlow, Dilip Nathwani, Peter Davey...
More informationSupplementary Online Content
Supplementary Online Content Torres A, Sibila O, Ferrer M, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory
More informationThe Importance of Fluid Management in Acute Lung Injury Secondary to Septic Shock
Original Research CRITICAL CARE MEDICINE The Importance of Fluid Management in Acute Lung Injury Secondary to Septic Shock Claire V. Murphy, PharmD; Garrett E. Schramm, PharmD; Joshua A. Doherty, BS; Richard
More informationDiagnosis of Ventilator-Associated Pneumonia: A Pilot, Exploratory Analysis of a New Score Based on Procalcitonin and Chest Echography
CHEST 2014; 146(6): 1578-1585 文献精读 Diagnosis of Ventilator-Associated Pneumonia: A Pilot, Exploratory Analysis of a New Score Based on Procalcitonin and Chest Echography Giovanni Zagli, MD, PhD ; Morena
More informationPneumonia in the Hospitalized
Pneumonia in the Hospitalized Patient: Use of Steroids Nicolette Myers, MD Pulmonary/Sleep/Critical Care November 9, 2018 Park Nicollet Clinic Facts About Pneumonia CAP is the 8 th most common cause of
More informationThe ARDS is characterized by increased permeability. Incidence of ARDS in an Adult Population of Northeast Ohio*
Incidence of ARDS in an Adult Population of Northeast Ohio* Alejandro C. Arroliga, MD, FCCP; Ziad W. Ghamra, MD; Alejandro Perez Trepichio, MD; Patricia Perez Trepichio, RRT; John J. Komara Jr., BA, RRT;
More informationUPDATE IN HOSPITAL MEDICINE
UPDATE IN HOSPITAL MEDICINE FLORIDA CHAPTER ACP MEETING 2016 Himangi Kaushal, M.D., F.A.C.P. Program Director Memorial Healthcare System Internal Medicine Residency DISCLOSURES None OBJECTIVES Review some
More informationEvaluation of Outcome for Intubated Patients with Pneumonia Due to Pseudomonas aeruginosa
973 Evaluation of Outcome for Intubated Patients with Pneumonia Due to Pseudomonas aeruginosa Jordi Rello, Paola Jubert, Jordi Valles, Antonio Artigas, Montse Rue, and Michael S. Niederman From the Department
More informationHEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION
HEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health Care Medical
More informationHEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY
HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health
More informationWeight of the IDSA/ATS minor criteria for severe community-acquired pneumonia *
Respiratory Medicine (2011) 105, 1543e1549 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Weight of the IDSA/ATS minor criteria for severe community-acquired pneumonia
More informationHospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia
Hospital-wide Impact of Mandatory Infectious Disease Consultation on Staphylococcus aureus Septicemia Amanda Guth 1 Amy Slenker MD 1,2 1 Department of Infectious Diseases, Lehigh Valley Health Network
More informationMethicillin-Resistant Staphylococcus aureus (MRSA) S urveillance Report 2008 Background Methods
Methicillin-Resistant Staphylococcus aureus (MRSA) Surveillance Report 2008 Oregon Active Bacterial Core Surveillance (ABCs) Office of Disease Prevention & Epidemiology Oregon Department of Human Services
More informationEpidemiology and Etiology of Community-Acquired Pneumonia 761 Lionel A. Mandell
LOWER RESPIRATORY TRACT INFECTIONS Preface Thomas M. File, Jr xiii Community-Acquired Pneumonia: Pathophysiology and Host Factors with Focus on Possible New Approaches to Management of Lower Respiratory
More informationChest radiography in patients suspected of pneumonia in primary care: diagnostic yield, and consequences for patient management
Chest radiography in patients suspected of pneumonia in primary care: diagnostic yield, and consequences for patient management 4 Speets AM, Hoes AW, Van der Graaf Y, Kalmijn S, Sachs APE, Mali WPThM.
More informationOnline Supplement for:
Online Supplement for: INFLUENCE OF COMBINED INTRAVENOUS AND TOPICAL ANTIBIOTIC PROPHYLAXIS ON THE INCIDENCE OF INFECTIONS, ORGAN DYSFUNCTIONS, AND MORTALITY IN CRITICALLY ILL SURGICAL PATIENTS A PROSPECTIVE,
More informationSupplementary Online Content
Supplementary Online Content Toyoda N, Chikwe J, Itagaki S, Gelijns AC, Adams DH, Egorova N. Trends in infective endocarditis in California and New York State, 1998-2013. JAMA. doi:10.1001/jama.2017.4287
More informationMAJOR ARTICLE. (See the editorial commentary by Mandell on pages 386 8)
MAJOR ARTICLE Severe Community-Acquired Pneumonia: Validation of the Infectious Diseases Society of America/ American Thoracic Society Guidelines to Predict an Intensive Care Unit Admission Adamantia Liapikou,
More informationA new measure of acute physiological derangement for patients with exacerbations of obstructive airways disease: The COPD and Asthma Physiology Score
Respiratory Medicine (2007) 101, 1994 2002 A new measure of acute physiological derangement for patients with exacerbations of obstructive airways disease: The COPD and Asthma Physiology Score Martin J.
More informationLinezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H
Linezolid for treatment of ventilator-associated pneumonia: a cost-effective alternative to vancomycin Shorr A F, Susla G M, Kollef M H Record Status This is a critical abstract of an economic evaluation
More informationCommunity Acquired Pneumonia: Measures to Improve Management and Healthcare Quality
Community Acquired Pneumonia: Measures to Improve Management and Healthcare Quality Gonzalo Bearman MD, MPH Assistant Professor of Internal Medicine Divisions of Quality Health Care & Infectious Diseases
More informationBrice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine
Brice Taylor Assistant Professor Division of Pulmonary and Critical Care Medicine Discuss advances in predicting prognosis Understand dwhat we know (and don t know) about the Microbiology Recognize important
More informationSeverity assessment of healthcareassociated pneumonia and pneumonia in immunosuppression
Eur Respir J 212; 4: 121 121 DOI: 1.1183/931936.187811 CopyrightßERS 212 Severity assessment of healthcareassociated pneumonia and pneumonia in immunosuppression Maria Carrabba*,#, Marina Zarantonello*,
More informationEvaluation of Vancomycin Continuous Infusion in Trauma Patients
OBJECTIVES Evaluation of Vancomycin Continuous Infusion in Trauma Patients Brittany D. Bissell, Pharm.D. PGY-2 Critical Care Pharmacy Resident Jackson Memorial Hospital Miami, Florida Evaluate the potential
More informationDefining prognostic factors in the elderly with community acquired pneumonia: a case controlled study of patients aged 75 yrs
Eur Respir J 2001; 17: 200 205 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 Defining prognostic factors in the elderly with community acquired
More informationSeverity prediction rules in community acquired pneumonia: a validation study
Thorax 2000;55:219223 219 Severity prediction rules in community acquired pneumonia: a validation study W S Lim, S Lewis, J T Macfarlane Respiratory Medicine, City Hospital, Nottingham NG5 1PB, UK W S
More informationTHE CLINICAL course of severe
ORIGINAL ARTICLE Improved Prediction of Outcome in Patients With Severe Acute Pancreatitis by the APACHE II Score at 48 Hours After Hospital Admission Compared With the at Admission Arif A. Khan, MD; Dilip
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationValidation of Scoring Systems for Predicting Severe Community-Acquired Pneumonia
ORIGINAL ARTICLE Validation of Scoring Systems for Predicting Severe Community-Acquired Pneumonia Hajime Fukuyama, Tadashi Ishida, Hiromasa Tachibana, Hiroaki Nakagawa, Masahiro Iwasaku, Mika Saigusa,
More informationNew Surveillance Definitions for VAP
New Surveillance Definitions for VAP 2012 Critical Care Canada Forum Toronto Dr. John Muscedere Associate Professor of Medicine, Queen s University Kingston, Ontario Presenter Disclosure Dr. J. G. Muscedere
More informationDoes Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
ISPUB.COM The Internet Journal of Infectious Diseases Volume 15 Number 1 Does Extending Clostridium Difficile Treatment In Patients Who Are Receiving Concomitant Antibiotics Reduce The Rate Of Relapse?
More informationClinical failure, community-acquired pneumonia, management, outcome, prognosis, risk-factors
ORIGINAL ARTICLE 10.1111/j.1469-0691.2006.01535.x Prognostic factors for early clinical failure in patients with severe community-acquired pneumonia M. Hoogewerf 1, J. J. Oosterheert 1, E. Hak 2, I. M.
More informationFacilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)
Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Data Analysis Plan: Apneic Oxygenation vs. No Apneic Oxygenation Background Critically ill patients
More informationMRSA Micro Scan Pos Combo 6J DADE BEHRING VCM
PKPD MRSA 1 1 2 1 1 2 17 1 26 17 3 16 vancomycinvcm methicillin-resistant Staphylococcus aureusmrsa 31 pharmacokineticpkparameter retrospective VCM 21 10 PK parameter Mann- Whitney U-test Cmax 37.1 µ gml29.942
More informationJohn Dallas MD, Sarah M Brown PhD, Karl Hock, Mitchell G Scott PhD, Lee P Skrupky PharmD, Walter A Boyle III MD and Marin H Kollef MD
Original Research Diagnostic Utility of Plasma Procalcitonin for Nosocomial Pneumonia in the Intensive Care Unit Setting John Dallas MD, Sarah M Brown PhD, Karl Hock, Mitchell G Scott PhD, Lee P Skrupky
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationWORKSHOP. The Multiple Facets of CAP. Community acquired pneumonia (CAP) continues. Jennifer s Situation
Practical Pointers pointers For for Your your Practice practice The Multiple Facets of CAP Dr. George Fox, MD, MSc, FRCPC, FCCP Community acquired pneumonia (CAP) continues to be a significant health burden
More informationPneumonia Caused by Methicillin-Resistant Staphylococcus aureus
SUPPLEMENT ARTICLE Pneumonia Caused by Methicillin-Resistant Staphylococcus aureus Ethan Rubinstein, 1 Marin H. Kollef, 2 and Dilip Nathwani 3 1 University of Manitoba, Winnipeg, Canada; 2 Washington University
More informationOriginal Article Mahidol Univ J Pharm Sci 2015; 42 (4), MT. Nguyen 1, TD. Dang Nguyen 1* 1
Original Article Mahidol Univ J Pharm Sci 2015; 42 (4), 195-202 Investigation on hospital-acquired pneumonia and the association between hospital-acquired pneumonia and chronic comorbidity at the Department
More informationThe Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia
The Value of Routine Microbial Investigation in Ventilator-Associated Pneumonia JORDI RELLO, MIGUEL GALLEGO, DOLORS MARISCAL, ROSARIO SOÑORA, and JORDI VALLES Intensive Care, Respiratory and Microbiology
More informationAPACHE II: A Severity of Disease Classification System Standard Operating Procedure for Accurate Calculations
BACKGROUND APACHE II: A Severity of Disease Classification System Standard Operating Procedure for Accurate Calculations The APACHE prognostic scoring system was developed in 1981 at the George Washington
More informationPERCUTANEOUS DILATATIONAL TRACHEOSTOMY
PERCUTANEOUS DILATATIONAL TRACHEOSTOMY GM KOKSAL *, NC SAYILGAN * AND H OZ ** Abstract Background: The aim of this study was to investigate the rate, timing, the incidence of complications of percutaneous
More informationInadequate Empiric Antibiotic Therapy among Canadian. Hospitalized Solid-Organ Transplant Patients: Incidence and Impact on Hospital Mortality
Inadequate Empiric Antibiotic Therapy among Canadian Hospitalized Solid-Organ Transplant Patients: Incidence and Impact on Hospital Mortality by Bassem Hamandi A thesis submitted in conformity with the
More informationValidation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia
1 Division of Respiratory and Critical Care Medicine, Department of Medicine, National University Hospital, Singapore; 2 Biostatistics Unit, Yong Loo Lin School of Medicine, National University of Singapore,
More informationComputed Tomography for the Diagnosis and Evaluation of the Severity of Community-acquired Pneumonia in the Elderly
ORIGINAL ARTICLE Computed Tomography for the Diagnosis and Evaluation of the Severity of Community-acquired Pneumonia in the Elderly Takahiro Haga 1,2, Mizuki Fukuoka 1,2, Mizuo Morita 1, Kohei Cho 1 and
More informationOptimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches
Optimizing Antibiotic Therapy in the ICU For Pneumonia Current and Future Approaches Andrew F. Shorr, MD, MPH Washington Hospital Center Georgetown Univ. Disclosures I have served as a consultant to, researcher/investigator
More informationThe IDSA/ATS consensus guidelines on the management of CAP in adults
The IDSA/ATS consensus guidelines on the management of CAP in adults F. Piffer F. Tardini R. Cosentini U.O. Medicina d'urgenza, Gruppo NIV, Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina
More informationSepsis 3.0: The Impact on Quality Improvement Programs
Sepsis 3.0: The Impact on Quality Improvement Programs Mitchell M. Levy MD, MCCM Professor of Medicine Chief, Division of Pulmonary, Sleep, and Critical Care Warren Alpert Medical School of Brown University
More informationCritical care resources are often provided to the too well and as well as. to the too sick. The former include the patients admitted to an ICU
Literature Review Critical care resources are often provided to the too well and as well as to the too sick. The former include the patients admitted to an ICU following major elective surgery for overnight
More informationMichael S. Niederman, M.D. Clinical Director Pulmonary and Critical Care Medicine New York Presbyterian Hospital Weill Cornell Medical Center
CA-MRSA Pneumonia Michael S. Niederman, M.D. Clinical Director Pulmonary and Critical Care Medicine New York Presbyterian Hospital Weill Cornell Medical Center Professor of Clinical Medicine Weill Cornell
More informationEDUCATIONAL COMMENTARY VANCOMYCIN MONITORING
EDUCATIONAL COMMENTARY VANCOMYCIN MONITORING Commentary provided by: Julie Hall, MHS, MT (ASCP) Assistant Dean, College of Health Professions Assistant Professor, Medical Laboratory Science Grand Valley
More informationNIV in acute hypoxic respiratory failure
All course materials, including the original lecture, are available as webcasts/podcasts at www.ers-education. org/niv2009.htm NIV in acute hypoxic respiratory failure Educational aims This presentation
More informationExclusion Criteria 1. Operator or supervisor feels specific intra- procedural laryngoscopy device will be required.
FELLOW Study Data Analysis Plan Direct Laryngoscopy vs Video Laryngoscopy Background Respiratory failure requiring endotracheal intubation occurs in as many as 40% of critically ill patients. Procedural
More informationPatterns of Resolution of Chest Radiograph Abnormalities in Adults Hospitalized with Severe Community-Acquired Pneumonia
MAJOR ARTICLE Patterns of Resolution of Chest Radiograph Abnormalities in Adults Hospitalized with Severe Community-Acquired Pneumonia Anke H. W. Bruns, 1 Jan Jelrik Oosterheert, 1 Mathias Prokop, 2 Jan-Willem
More informationJCP Online First, published on June 17, 2013 as /jclinpath Original article
JCP Online First, published on June 17, 2013 as 10.1136/jclinpath-2012-201209 Original article Diagnostic, therapeutic and economic consequences of a positive urinary antigen test for Legionella spp. in
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationDilemmas in Septic Shock
Dilemmas in Septic Shock William Janssen, M.D. Assistant Professor of Medicine National Jewish Health University of Colorado Denver Health Sciences Center A 62 year-old female presents to the ED with fever,
More informationTrial protocol - NIVAS Study
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 Trial protocol - NIVAS Study METHODS Study oversight The Non-Invasive Ventilation after Abdominal Surgery
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationOHSU. Update in Sepsis
Update in Sepsis Jonathan Pak, MD June 1, 2017 Structure of Talk 1. Sepsis-3: The latest definition 2. Clinical Management - Is EGDT dead? - Surviving Sepsis Campaign Guidelines 3. A novel therapy: Vitamin
More informationSimplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data
ORIGINAL ARTICLE RESPIRATORY INFECTIONS Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data Waleed Salih, Stuart Schembri and James D. Chalmers Affiliations:
More informationPneumococcal pneumonia
Pneumococcal pneumonia Wei Shen Lim Consultant Respiratory Physician & Honorary Professor of Medicine Nottingham University Hospitals NHS Trust University of Nottingham Declarations of interest Unrestricted
More informationResearch Article Eosinophil as a Protective Cell in S. aureus Ventilator-Associated Pneumonia
Hindawi Publishing Corporation Mediators of Inflammation Volume 2013, Article ID 152943, 5 pages http://dx.doi.org/10.1155/2013/152943 Research Article Eosinophil as a Protective Cell in S. aureus Ventilator-Associated
More informationExternal Validation of the Acute Physiology and Chronic Health Evaluation II in Korean Intensive Care Units
Original Article http://dx.doi.org/10.3349/ymj.2013.54.2.425 pissn: 0513-5796, eissn: 1976-2437 Yonsei Med J 54(2):425-431, 2013 External Validation of the Acute Physiology and Chronic Health Evaluation
More informationEarly-goal-directed therapy and protocolised treatment in septic shock
CAT reviews Early-goal-directed therapy and protocolised treatment in septic shock Journal of the Intensive Care Society 2015, Vol. 16(2) 164 168! The Intensive Care Society 2014 Reprints and permissions:
More information